Alkermes plc (ALKS)
$
30.1
-0.63 (-2.09%)
Key metrics
Financial statements
Free cash flow per share
0.0032
Market cap
5 Billion
Price to sales ratio
3.3675
Debt to equity
0.0385
Current ratio
2.0591
Income quality
0
Average inventory
193.8 Million
ROE
0.1445
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Alkermes plc, a biopharmaceutical company founded in 1987 and headquartered in Dublin, Ireland, focuses on researching, developing, and commercializing pharmaceutical products to meet the unmet medical needs of patients in various therapeutic areas. The company has a strong market presence, reporting substantial revenue of $1,475,899,000.00 which underscores its operational success. The EBITDA ratio stands at 0.22 highlighting the company's operational efficiency. Furthermore, the earnings per share (EPS) is reported at $1.47 indicating profitability on a per-share basis. Alkermes also earned an interest income of $45,304,000.00 showcasing its ability to generate returns from financial investments. Additionally, the net total of other income and expenses is reported at $37,494,000.00 reflecting the impact of non-core financial activities on the overall financial standing of the company. Among its marketed products are ARISTADA, VIVITROL, and VUMERITY, which address critical psychiatric and neurological conditions, emphasizing the company’s commitment to addressing diverse health challenges. Positioned as a key player in the Biotechnology industry, Alkermes contributes significantly to the overall market landscape while belonging to the Healthcare sector, driving innovation and growth. The stock is affordable at $27.79 making it suitable for budget-conscious investors. With a mid-range market capitalization of $4,970,037,021.00 the company is considered a steady performer in the market. Furthermore, the stock has a high average trading volume of 1,924,625.00 indicating strong liquidity and investor interest. Alkermes demonstrates a robust portfolio that includes not only marketed products but also promising drug candidates in development, such as LYBALVI and nemvaleukin alfa, which aim to further expand the treatment options available to patients.
Is Alkermes plc (ALKS) a good investment?
Investing in Alkermes plc (ALKS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bearish outlook. Always conduct your own research before investing.
What is Alkermes plc (ALKS)'s stock forecast?
Analysts predict Alkermes plc stock to fluctuate between $25.17 (low) and $36.32 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Alkermes plc's market capitalization?
As of 2026-02-27, Alkermes plc's market cap is $4,970,037,021, based on 165,117,509 outstanding shares.
How does Alkermes plc compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Alkermes plc has a Lower Market-Cap, indicating a difference in performance.
How can I buy Alkermes plc (ALKS) stock?
To buy Alkermes plc (ALKS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALKS. Place an order (Market, Limit, etc.).
What is the best time to invest in Alkermes plc?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Alkermes plc stock ever split?
Alkermes plc's last stock split was 2:1 on 2000-05-15.
How did Alkermes plc perform in the last earnings report?
Revenue: $1,475,899,000 | EPS: $1.47 | Growth: -33.78%.
Where can I find Alkermes plc's investor relations reports?
Visit https://www.alkermes.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Alkermes plc?
You can explore historical data from here
What is the all-time high and low for Alkermes plc stock?
All-time high: $36.45 (2025-02-18) | All-time low: $21.24 (2021-12-01).
What are the key trends affecting Alkermes plc stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
defenseworld.net
Alkermes (NASDAQ: ALKS) executives highlighted a "strong and eventful" 2025 and outlined a 2026 plan focused on expanding the company's commercial platform following its Avadel acquisition while advancing its orexin pipeline, led by alixorexton, into late-stage development. Management also announced a CEO transition, with longtime chief executive Richard Pops set to step down this summer and
zacks.com
ALKS beats Q4 earnings and revenue estimates, but shares fall 7%. The company announces a CEO transition plan.
zacks.com
While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
seekingalpha.com
Alkermes plc (ALKS) Q4 2025 Earnings Call Transcript
zacks.com
Here is how Alkermes (ALKS) and American Well Corporation (AMWL) have performed compared to their sector so far this year.
zacks.com
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
businesswire.com
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) (“Alkermes”) and Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel”) today announced Alkermes' completion of its acquisition of Avadel, a commercial-stage biopharmaceutical company. The acquisition adds Avadel's FDA-approved product, LUMRYZ®, to Alkermes' commercial portfolio, and provides Alkermes with a commercial organization experienced in this disease state. This strategic move accelerates Alkermes' entry into the sleep medicine market.
zacks.com
Here is how Alkermes (ALKS) and CASI Pharmaceuticals Inc. (CASI) have performed compared to their sector so far this year.
zacks.com
Here is how Alkermes (ALKS) and CASI Pharmaceuticals Inc. (CASI) have performed compared to their sector so far this year.
zacks.com
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
See all news
